Gefapixant Citrate

CAS no.: 2310299-91-1

Type: API

Usage: Chronic cough

Technical description
Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC and received subsequent approval in the EU in September 2023 for the same indications. It is the first therapy to be approved for the treatment of RCC or UCC in the EU.

IUPAC name: 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide;2-hydroxypropane-1,2,3-tricarboxylic acid.

Molecular formula: C₂₀H₂₇N₅O₁₁S

Molecular Weight: 545.5 g/mol

Class: Is a P2X3 receptor antagonist.

Synonyms: MK-7264 citrate, AF-219 citrate, RO4926219 citrate.